• Users Online: 122
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 8  |  Issue : 1  |  Page : 19-25

Moxifloxacin in situ gel as an adjunct in the treatment of periodontal pocket: A clinico-microbiological study


1 Department of Periodontics and oral Implantology, Sri Hasanamba Dental College and Hospital, Hassan, Karnataka, India
2 Yenepoya Pharmacy College and Research Center, Mangalore, Karnataka, India
3 Department of Oral Pathology, Farooqia Dental College and Hospital, Mysore, Karnataka, India
4 Department of Periodontics, AECS Maruti Dental College and Hospital, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Shivamurthy Ravindra
Department of Periodontics and Oral Implantology, JSS Dental Collage, Mysore, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijohs.ijohs_33_17

Rights and Permissions

Context: Periodontal diseases considered as the infectious condition of the periodontium. The prevalence of these diseases can be reduced by mechanical plaque removal along with systemic and locally delivered antimicrobial agents. Moxifloxacin in situ gel was evaluated as an adjunct to scaling and root planing as local drug delivery (LDD) for its efficacy in the treatment of chronic periodontitis. Aims: The aim of the study was to evaluate the efficacy of moxifloxacin as LDD in the treatment of chronic periodontitis. Settings and Design: Study design was randomized control trial. Subjects and Methods: Sixty-seven sites from chronic periodontitis patients of age 25–65 years with a pocket depth of >5 mm, showing radiographic evidence of bone loss were included in the study. The scaling and root planing (SRP) was performed for all the patients and randomly divided into three groups: Group A: SRP + moxifloxacin in situ gel, Group B: SRP + chlorhexidine in situ gel, and Group C: Control group received SRP as monotherapy. The clinical and microbiological parameters were recorded at baseline, 6th week, and 3 months. Statistical Analysis Used: Data were subjected to statistical analysis with repeated analysis of varience and paired t-test using SPSS (V.22) IBM Corporation, Washington, DC, United States) software. Results: All the three groups showed improvement in both clinical and microbial parameters, but at the end of the 3rd month, Group A showed highly significant results in comparison with Group B and Group C. Conclusions: Moxifloxacin showed more gain in clinical attachment level, and reduction in probing depth and in situ gel can be used as a safe vehicle to deliver the drug locally.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed432    
    Printed12    
    Emailed0    
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal